Home > Haematology > ASH 2021 > Multiple Myeloma > MajesTEC-1: Teclistamab efficacious in heavily pre-treated MM

MajesTEC-1: Teclistamab efficacious in heavily pre-treated MM

Presented by
Prof. Philippe Moreau, University Hospital of Nantes, France
Conference
ASH 2021
Trial
Phase 1/2, MajesTEC-1
Teclistamab was safe and efficacious in patients with relapsed/refractory multiple myeloma (MM). The results of the phase 1/2 MajesTEC-1 trial showed durable and deepening responses in a triple-class exposed population. A phase 3 study, MajesTEC-3, is currently ongoing to further assess teclistamab in patients with MM [1].

Teclistamab is an off-the-shelf, T cell-directing antibody binding to CD3 on T cells and BCMA on plasma cells. The open-label, multicentre, phase 1/2 MajesTEC-1 trial (NCT04557098) included patients with relapsed/refractory MM who received at least 3 prior lines of therapy and were triple-class exposed (n=165). The patients were treated with 1.5 mg/kg teclistamab, subcutaneously administered once weekly. The primary endpoint was the overall response rate. Prof. Philippe Moreau (University Hospital of Nantes, France) presented the latest update of this trial.

At a median follow-up of 7.8 months, the overall response rate was 62.0%. In addition, 58% of the patients achieved a very good partial response or better, and 29% of the patients reached a complete response or better. The median time to first response was 1.2 months and the median time to best response was approximately 3 months. The results were consistent across subgroups, including older patients, patients with high-risk cytogenetics, and triple-class refractory patients. The 9-month event-free survival rate for responders was 85.9%. Prof. Moreau added that the responses were durable and tended to deepen over time.

Teclistamab was generally well tolerated, with no patients requiring dose reduction. The most common haematologic adverse events were neutropenia (65.5%), anaemia (49.7%), thrombocytopenia (38.2%), and lymphopenia (33.9%). Cytokine-release syndrome occurred in 71.5% of the patients; only 1 grade 3 case was reported, but this case resolved without treatment discontinuation. The grade 3 or 4 infection rate was 35.2%, which is not unexpected in this heavily pre-treated population. ICANS events were uncommon, all mild or moderate, and resolved without treatment discontinuation.

Prof. Moreau concluded that teclistamab showed an unprecedented response rate for a non-cellular therapy in triple-class-exposed patients with relapsed/refractory MM. The durable and deepening responses are encouraging. Multiple trials are currently running to further evaluate this novel agent.

  1. Moreau P, et al. Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. Abstract 896, ASH 2021 Annual Meeting, 11‚Äď14 December.

 

Copyright ©2022 Medicom Medical Publishers



Posted on